Supporting patients with acute respiratory distress syndrome (ARDS), remains a critical challenge in intensive care units ...

InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.

Peer-reviewed publication in “The Oncologist” is now available onlineInvestigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day ...

As fans eagerly await the return of STAT on January 6, the tension surrounding Siméon’s fate has captured the audience’s attention. This article delves into the key plot poin ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

Key 2026 milestones for SeaStar Medical include the following: Broaden QUELIMMUNE adoption to include 15 additional top-ranked children’s medical centers, more than doubling the total number of sites ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...

Infectious disease researchers have identified Pteropine orthoreoviruses (PRVs), a group of newly emergent bat-borne viruses, ...